Streamex 향후 성장
Future 기준 점검 5/6
Streamex은 연간 수입과 매출이 각각 114.5%와 106.4% 증가할 것으로 예상되고 EPS는 연간 117.5%만큼 증가할 것으로 예상됩니다.
핵심 정보
114.5%
이익 성장률
117.50%
EPS 성장률
| Medical Equipment 이익 성장 | 16.1% |
| 매출 성장률 | 106.4% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 21 May 2026 |
최근 향후 성장 업데이트
Recent updates
새로운 내러티브 • Apr 09
Tokenized Commodity Yield Platform Will Benefit From Growing Real World Asset Adoption
Catalysts About Streamex Streamex operates a capital light platform focused on tokenized commodity assets such as yield bearing gold and planned silver, copper and energy linked products. What are the underlying business or industry changes driving this perspective?분석 기사 • Dec 12
Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now
Key Insights BioSig Technologies will host its Annual General Meeting on 18th of December Salary of US$865.7k is part...분석 기사 • Dec 14
Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why
Shareholders of BioSig Technologies, Inc. ( NASDAQ:BSGM ) will have been dismayed by the negative share price return...Seeking Alpha • Oct 07
BioSig in acquisition pact with San Antonio Hospital for cardiac signal system
Medical device maker BioSig Technologies, Inc. (NASDAQ:BSGM) announced that the company entered into a purchase agreement with San Antonio Methodist Hospital allowing the latter to acquire its PURE EP System, a cardiac signal processing system. According to a regulatory filing on Thursday, the company executed the deal on Sep. 30 In July, BSGM announced a leasing deal under which the Overland Park Regional Medical Center agreed to acquire the PURE EP System, marking the first transaction since its nationwide launch. "Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," BSGM Chief Commercial Officer Gray Fleming said at the time. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology," he added.Seeking Alpha • Sep 08
BioSig: No Changes To Hold Thesis Following Q2 Earnings
Summary BioSig continues to be presented with systematic challenges that place it behind other selective opportunities in med-tech. Cash flows are priced out well into the future and the predictability of these is low in the current landscape. We note updates around PURE EP continue to receive a muted market reaction upon release. Here we reiterate the hold rating on BSGM. From the Portfolio Manager's Desk Unprofitable med-tech continues to face systematic headwinds as the market looks to match mispricings in fundamentals to future expectations. However, risk-assets have caught a bid since June and that's meant high-beta names have clawed back some of the losses incurred in FY22. We've made no changes to our thesis on BioSig Technologies, Inc. (BSGM) from my previous analysis in June. We also covered BioSig in late 2020. We encourage investors to factor a data driven approach in this name until there is some fundamental value to be derived. Investment Summary We reiterate a hold rating on BSGM following Q2 earnings as systematic headwinds remain for this name. We note the stock has caught a bid since the June bounce however we argue this is likely beta related rather than some unidentified or uncorrelated premia BSGM is presenting relative to peers. With cash flows still priced well out into the future, BSGM is one to be watched from the sidelines from now for a defensively positioned equity portfolio. Rate hold on a $1 valuation. Risks to investment thesis Investing in small-cap equities comes with inherent risks that must be factored in before investment decision. Moreover, investing in commercial stage medical device companies carries its own set of downside risks. Being a neutral stance, there is both upside and downside risks to our investment thesis. In addition, small-cap equities can become disconnected from fundamentals upon news releases or wider market actions and display wide volatility in price swings. These risks pose a threat to this investment thesis and must be considered heavily into one's investment reasoning when reading this analysis. Recent upside likely beta related Quantitative analysis of recent stock returns points to the fact the upside is likely due to equity market and sector-beta rather than company-specific risk premia. As seen in Exhibit 1, since the leg upward from the July bounce, BSGM's equity beta to the S&P/500 also shifted well above 1 and has remained buoyant since. This tells us that investors are buyers of BGSM in seeking strategic equity/health care exposure, versus tactical positioning from active managers/investors. Exhibit 1. Up-shift in covariance structure accompanying the latest leg in the BGSM share price suggesting recent upside is likely equity beta versus idiosyncratic risk/return Data: Updata Further evidence of the above is seen in Exhibit 2. As noted, health care as an investment universe has caught a bid since the June bounce along with positioning in risk-assets. However, we note that BSGM's correlation to the medical devices and health care index equipment has also shifted up since May. As a result, we question if the recent upside is a function of certain investors having identified in BGSM that the market consensus has overlooked, or, just a function of sector-beta, as mentioned. We are leaning towards the latter. Exhibit 2. Correlations to med-tech and health care benchmarks also lifting since early May raising questions on where we can attribute the source of recent equity returns from in BGSM Both charts [above and below] demonstrate a tight dispersion between equity market and sector beta and the BGSM share price since it began to tick up in August Data: Updata Pure EP updates still priced in As has been the case with BSGM, the growth engine centres around PURE EP and updates around the same. However, as has also been the case this year, investors have priced in additional updates quickly and with little amplitude. Most recently on 24 August it reported that it had installed a second evaluation system at the Cleveland Clinic, expanding physician access to the company's 'signal' technology. However, the market's reaction was mute, as has been the case previously. In particular, we note the market's muted reaction to the news BSGM will reduce product evaluations down to 60 days from 180-360 days. However, there's still no revenue booked for the segment, in preparation for the commercial rollout. We mentioned in June that, "BSGM likely has revenue tailwinds set to be realised in H2 FY22, with a ramp up in sales predicted into the coming years pending a successful launch." This likely has been overshot and we now look to Q4 to see some form of how the company intends to proceed with its sales strategy looking ahead. The question then turns to what exactly are we paying for today in BSGM. Shares are priced at more than 7.1x book value, on shareholder equity of $6.8mm and book value per share of $0.15. It's also priced at 6.6x enterprise value ("EV") to book value. At this multiple we'd be paying an implied price of $1.00, suggesting the market consensus has the stock fairly discounted at its current market capitalization. Moreover, and looking at the balance sheet, we're buying into a capital structure that is weighted towards equity holders, with $596mm in tangible assets and $317mm in patents that it amortizes on a straight-line basis over 20 years. However, we're not buying into any substantiated return on any of this capital investment, and we are set to pay what looks like fair value for cash flows priced well out into the future. This degree of uncertainty keeps us trigger shy on the name. Technical factors With a lack of fundamental data, we checked the market's psychology around the stock and noted there remains a downside bias in price action. As seen in Exhibit 3, there are downside targets clustered towards the $0.85-$0.92 region. The stock has set a series of lower highs and is again testing the inner resistance line shown below. From this chart, price action appears to be bearish, and unsupportive of near-term upside.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 282 | 195 | N/A | N/A | 1 |
| 12/31/2027 | 97 | 59 | N/A | N/A | 1 |
| 12/31/2026 | 8 | -51 | N/A | N/A | 1 |
| 3/31/2026 | N/A | -507 | -20 | -20 | N/A |
| 12/31/2025 | N/A | -463 | -10 | -10 | N/A |
| 9/30/2025 | 0 | -40 | -8 | -8 | N/A |
| 6/30/2025 | 0 | -26 | -4 | -4 | N/A |
| 3/31/2025 | 0 | -10 | -5 | -5 | N/A |
| 12/31/2024 | 0 | -11 | -5 | -5 | N/A |
| 9/30/2024 | 0 | -15 | -7 | -7 | N/A |
| 6/30/2024 | 0 | -18 | -10 | -10 | N/A |
| 3/31/2024 | 0 | -25 | -13 | -13 | N/A |
| 12/31/2023 | 0 | -29 | -17 | -17 | N/A |
| 9/30/2023 | 0 | -30 | -19 | -18 | N/A |
| 6/30/2023 | 0 | -32 | -20 | -20 | N/A |
| 3/31/2023 | 0 | -27 | -22 | -21 | N/A |
| 12/31/2022 | 0 | -27 | -22 | -22 | N/A |
| 9/30/2022 | 0 | -29 | -24 | -23 | N/A |
| 6/30/2022 | 0 | -30 | -26 | -25 | N/A |
| 3/31/2022 | 0 | -32 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -32 | -27 | -26 | N/A |
| 9/30/2021 | 0 | -34 | -27 | -27 | N/A |
| 6/30/2021 | 0 | -38 | -27 | -26 | N/A |
| 3/31/2021 | 0 | -49 | -28 | -28 | N/A |
| 12/31/2020 | N/A | -52 | -27 | -27 | N/A |
| 9/30/2020 | N/A | -57 | -25 | -24 | N/A |
| 6/30/2020 | N/A | -51 | -22 | -22 | N/A |
| 3/31/2020 | N/A | -40 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -34 | N/A | -15 | N/A |
| 9/30/2019 | N/A | -25 | N/A | -15 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -13 | N/A |
| 3/31/2019 | N/A | -21 | N/A | -11 | N/A |
| 12/31/2018 | N/A | -18 | N/A | -10 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -10 | N/A |
| 6/30/2018 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2018 | N/A | -12 | N/A | -8 | N/A |
| 12/31/2017 | N/A | -13 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -10 | N/A | -6 | N/A |
| 6/30/2017 | N/A | -9 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -12 | N/A | -6 | N/A |
| 12/31/2016 | N/A | -12 | N/A | -5 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -11 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -9 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -5 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -4 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: STEX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.
수익 vs 시장: STEX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: STEX 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: STEX 의 수익(연간 106.4%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: STEX 의 수익(연간 106.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: STEX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 05:34 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Streamex Corp.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Todaro | Needham & Company |
| Scott Henry | Roth Capital Partners |